Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

Novian Health Receives FDA Approval to Study Breast Cancer Therapy (14 July 2011)

July 14, 2011 by Novian Health

Novian Health Receives FDA Approval to Study Breast Cancer Therapy
July 14, 2011 08:15 AM Eastern Daylight Time

CHICAGO–(BUSINESS WIRE)–Novian Health, developer of Novilase® Breast Therapy, announced that the US Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval for the company to start a multi-center study of its Novilase® Interstitial Laser Therapy (ILT) System. Novian developed the ILT System for the ablation of small (up to 20 mm) malignant breast tumors. Novilase has previously received FDA 510(k) clearance for the treatment of breast fibroadenomas.

“It will be another boon for patients when this therapy can be applied to cancerous breast tumors.”

Novilase ILT uses parametrically controlled heating to ablate tumors. The procedure is performed with either ultrasound or stereotactic x-ray imaging guidance and two small 14-gauge probes. It is intended to be a minimally-invasive alternative to lumpectomy.

An IDE allows the investigational device to be used in a clinical study designed to collect safety and effectiveness data. The data is required to support a Premarket Approval (PMA) application to the FDA. The study is scheduled to begin in the fourth quarter of 2011.

Patients enrolled in the study will undergo Novilase ILT of a malignant breast tumor. Following the procedure, imaging and an excision to remove the ablated tissue will be performed no later than 28 days post-ablation. The researchers will then collect data to confirm the tumor has been destroyed and correlate the post-ablation imaging (i.e., MR, ultrasound, and x-ray) with pathology. Data collected will be used to support a future study which will treat malignant breast tumors with Novilase ILT and followed with imaging.

“I’m pleased that the company was able to secure the IDE approval despite a challenging regulatory environment,” said Henry “Chip” Appelbaum, President and CEO of Novian Health.

The new multi-center study follows a single-site feasibility study on malignant tumors that was conducted at Rush University Medical Center by Kambiz Dowlat, M.D. After receiving 510(k) clearance, Novian Health launched its American Breast Laser Ablation Therapy Evaluation (ABLATE) registry. This data collection program tracks the progress of women who receive Novilase Breast Therapy.

“The potential benefit offered by Novilase has extended the treatment options for our patients in terms of non-surgical removal of non-malignant tumors,” said Barbara Schwartzberg, M.D., a leading breast surgeon in Denver, Colorado. “It will be another boon for patients when this therapy can be applied to cancerous breast tumors.”

Dr. Schwartzberg is chairwoman of the Cancer Committee at Rose Medical Center (Denver, Colorado.) and a member of Novian Health’s Scientific Advisory Board.

About Novilase

Novilase is a laser-based device for destroying tumors. This minimally invasive alternative to conventional surgery provides a patient with a safe tumor treatment alternative while preserving the patient’s options for additional procedures or adjunctive therapies. This outpatient procedure does not require general anesthetic or a hospital stay. Multiple tumors can be treated during a single visit. Therapy outcomes may be assessed using a variety of currently available imaging technologies and other methods. Therapy consists of physician placement of two small gauge needles into the tumor site after local anesthetic, followed by initiation of the computer-controlled Novilase system. Treatment times vary from 15-30 minutes.

About Novian Health

Novian Health Inc., located in Chicago, is a privately held company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). Developed as an alternative to surgery, the company’s technology uses parametrically controlled heating for the ablation of tumors. Treatment of breast tumors is the first application of the technology although Novilase has the potential to treat tumors elsewhere in the body.
For more information, call (312) 266-7200 or access www.novianhealth.com.

Contacts
Dowling & Dennis Public Relations
Liz Dowling, 415-388-2794
Liz@DowlingDennis.net

Download PDF

Related Posts

  • Novian Health Founder Is Honored as Breast Cancer Leader by Chicago Komen Affiliate (20 Oct 2011)
  • Novian Health Awarded New Patent for Breast Tumor Treatment Technology (28 Sept 2011)
  • Novian Health Awarded New Patent for Breast Cancer Treatment Technology (05 Dec 2013)
  • Novian Health Closes $11 Million in Funding for Breast Cancer Clinical Trials (04 Feb 2013)
  • Novian Health Presents at William Blair Private Conference

Filed Under: Press Release 2011

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by